Landscapes / Targets
JAK
22 drugs act on JAK, in 128 active trials · Any stage · updated 18 Nov 2026
FollowEvery change as it happens, and a Monday email
Drugs22
| Drug | How it works | Company | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Janus kinase inhibitor |
Bristol Myers Squibb · Public BMY |
Approved | 18 Nov 2026soonPhase 3 trial completes | ||
| How it works | Blocks JAK enzymes that pass on immune signals | ||||
| Next date | 18 Nov 2026 · Phase 3 trial completes | ||||
| Also tested for | Plaque Psoriasis, Psoriatic Arthritis and 9 more | ||||
| Open drug page | |||||
Janus kinase inhibitor |
Approved in the EU | 20 Nov 2026soonPhase 2 trial completes | |||
| How it works | Blocks JAK enzymes that pass on immune signals | ||||
| Next date | 20 Nov 2026 · Phase 2 trial completes | ||||
| Also tested for | Hidradenitis Suppurativa (HS), NonSegmental Vitiligo and 2 more | ||||
| Open drug page | |||||
Janus kinase inhibitor |
AbbVie · Public ABBV |
Approved | Nov 2026soonPhase 3 trial completes | ||
| How it works | Blocks JAK enzymes that pass on immune signals | ||||
| Next date | Nov 2026 · Phase 3 trial completes | ||||
| Also tested for | Atopic Dermatitis, Rheumatoid Arthritis and 13 more | ||||
| Open drug page | |||||
Janus kinase inhibitor |
Pfizer · Public PFE |
Approved | 2 Dec 2026soonPhase 3 trial completes | ||
| How it works | Blocks JAK enzymes that pass on immune signals | ||||
| Next date | 2 Dec 2026 · Phase 3 trial completes | ||||
| Also tested for | Alopecia Areata, Severe Alopecia Areata and 5 more | ||||
| Open drug page | |||||
Kinase inhibitor |
Approved | 30 Dec 2026Phase 2 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | 30 Dec 2026 · Phase 2 trial completes | ||||
| Also tested for | Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis and 3 more | ||||
| Open drug page | |||||
Janus kinase inhibitor |
Approved in China | Dec 2026Phase 1/2 trial completes | |||
| How it works | Blocks JAK enzymes that pass on immune signals | ||||
| Next date | Dec 2026 · Phase 1/2 trial completes | ||||
| Also tested for | Myelofibrosis, Chronic Graft Versus Host Disease and 1 more | ||||
| Open drug page | |||||
Janus kinase inhibitor |
Pfizer · Public PFE |
Approved | 17 Mar 2027Phase 3 trial completes | ||
| How it works | Blocks JAK enzymes that pass on immune signals | ||||
| Next date | 17 Mar 2027 · Phase 3 trial completes | ||||
| Also tested for | Ulcerative Colitis | ||||
| Open drug page | |||||
Ruxolitinibnot checked |
Kinase Inhibitor; janus kinase inhibitor |
Incyte +1 · Public NVS |
Approved | 30 Apr 2027Phase 3 trial completes | |
| How it works | Blocks JAK enzymes that pass on immune signals | ||||
| Next date | 30 Apr 2027 · Phase 3 trial completes | ||||
| Also tested for | Hidradenitis Suppurativa, Primary Myelofibrosis and 35 more | ||||
| Open drug page | |||||
Janus kinase inhibitor |
Pfizer · Public PFE |
Approved | 2 May 2027Phase 3 trial completes | ||
| How it works | Blocks JAK enzymes that pass on immune signals | ||||
| Next date | 2 May 2027 · Phase 3 trial completes | ||||
| Also tested for | Atopic Dermatitis, Eczema | ||||
| Open drug page | |||||
JAK1/JAK2 inhibitor |
Sun Pharma · Public SUNPHARMA.NS |
Approved | May 2027Phase 2/3 trial completes | ||
| Next date | May 2027 · Phase 2/3 trial completes | ||||
| Also tested for | Alopecia Areata | ||||
| Open drug page | |||||
Janus kinase inhibitor |
Approved | 4 Jun 2027Phase 2 trial completes | |||
| How it works | Blocks JAK enzymes that pass on immune signals | ||||
| Next date | 4 Jun 2027 · Phase 2 trial completes | ||||
| Also tested for | Palmoplantar Pustulosis, Lichen Sclerosus | ||||
| Open drug page | |||||
JAK inhibitor |
Approved in the EU | Jun 2027Phase 3 trial completes | |||
| How it works | Blocks JAK enzymes that pass on immune signals | ||||
| Next date | Jun 2027 · Phase 3 trial completes | ||||
| Also tested for | Axial Spondyloarthritis, Ulcerative Colitis and 2 more | ||||
| Open drug page | |||||
JAK inhibitor |
Approved in Japan | 30 Nov 2027Phase 4 trial completes | |||
| How it works | Blocks JAK enzymes that pass on immune signals | ||||
| Next date | 30 Nov 2027 · Phase 4 trial completes | ||||
| Also tested for | Ulcerative Colitis | ||||
| Open drug page | |||||
Janus kinase inhibitor |
Approved in China | 30 Nov 2027Phase 3 trial completes | |||
| How it works | Blocks JAK enzymes that pass on immune signals | ||||
| Next date | 30 Nov 2027 · Phase 3 trial completes | ||||
| Also tested for | Peripheral T-cell Lymphoma, T-cell Lymphomas | ||||
| Open drug page | |||||
Janus kinase inhibitor |
Eli Lilly · Public LLY |
Approved | Mar 2028Phase 3 trial completes | ||
| How it works | Blocks JAK enzymes that pass on immune signals | ||||
| Next date | Mar 2028 · Phase 3 trial completes | ||||
| Also tested for | Diabetes Mellitus, Type 1, Juvenile Idiopathic Arthritis and 8 more | ||||
| Open drug page | |||||
Janus kinase inhibitor |
Priovant Therapeutics +1 · Public PFE |
Approved | 31 Dec 2028Phase 2/3 trial completes | ||
| How it works | Blocks JAK enzymes that pass on immune signals | ||||
| Next date | 31 Dec 2028 · Phase 2/3 trial completes | ||||
| Also tested for | Cutaneous Sarcoidosis, Lichen Planopilaris | ||||
| Open drug page | |||||
Janus kinase inhibitor |
Approved | — | |||
| How it works | Blocks JAK enzymes that pass on immune signals | ||||
| Also tested for | Uveitis, Posterior, Uveitis, Intermediate and 1 more | ||||
| Open drug page | |||||
Janus kinase inhibitor |
Phase 3 | 5 Feb 2027Phase 2 trial completes | |||
| How it works | Blocks JAK enzymes that pass on immune signals | ||||
| Next date | 5 Feb 2027 · Phase 2 trial completes | ||||
| Also tested for | Psoriatic Arthritis, Crohn's Disease and 5 more | ||||
| Open drug page | |||||
Janus kinase inhibitor |
Phase 3 | 1 Dec 2027Phase 2 trial completes | |||
| How it works | Blocks JAK enzymes that pass on immune signals | ||||
| Next date | 1 Dec 2027 · Phase 2 trial completes | ||||
| Also tested for | Plaque Psoriasis, SLE and 4 more | ||||
| Open drug page | |||||
Janus kinase inhibitor |
Phase 1/2 | Apr 2027Phase 1/2 trial completes | |||
| How it works | Blocks JAK enzymes that pass on immune signals | ||||
| Next date | Apr 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Lymphoma, Non-small Cell Lung Cancer and 2 more | ||||
| Open drug page | |||||
No drugs match “”.
About this list
- Checked
- 20 of 22 drugs. The other 2 are marked “not checked” in the list. How we check
- Matches
- The mechanism of checked drugs, and drug names, so a drug not checked yet may be missing.
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · openFDA updated 17 Nov 2026